Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven Target Discovery Engine

July 7, 2022 0

Insilico Medicine Insilico Medicine is a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is …

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

July 6, 2022 0

Vertex Pharmaceuticals VX-880 for Type 1 Diabetes Vertex Pharmaceuticals (VRTX) announced that the FDA has lifted …

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

July 5, 2022 0

CureVac N.V. Files Lawsuit Against BioNTech for Infringement CureVac N.V. (CVAC), a company that develops therapeutics …

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

July 2, 2022 0

Celldex Therapeutics Interim Trial Data for Barzolvolimab Interim data from Celldex Therapeutics (CLDX) Phase 1b clinical …

Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

June 29, 2022 0

Kite Pharma - A Gilead Company In The NEWS Gilead Sciences' (GILD) firm Kite Pharma, announced …

Akero Therapeutics: Two Financing Transactions with Pfizer and Hercules Capital

June 27, 2022 0

Akero Therapeutics Financing Transactions Akero Therapeutics (AKRO) is one of the selected firms for the Prohost …

Health Canada Approved Amylyx Pharmaceuticals’ Product ALBRIOZA for Amyotrophic Lateral Sclerosis

June 23, 2022 0

The Great News from Amylyx Pharmaceuticals On Jun. 13, 2022, Amylyx Pharmaceuticals (AMLX) announced that Health …

Inflation and the Stock Market. ASCO: Different Data’s Presentations Promising to Defeat Solid Tumors

June 10, 2022 0

Inflation and the Stock Market Inflation, which we were told was but a temporary passing phenomenon, …

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

June 2, 2022 0

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb (BMY) product deucravacitinib has demonstrated positive results from the Phase …

Vertex Pharmaceuticals and Type 1 Diabetes

May 31, 2022 0

Vertex Pharmaceuticals to Announce New Data on VX-880 Clinical Trial Vertex Pharmaceuticals (VRTX) announced three abstracts, …

Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News

May 31, 2022 0

Regeneron Pharmaceuticals Acquisition of Checkmate Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced a successful acquisition of Checkmate Pharmaceuticals, …

The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

May 27, 2022 0

United Therapeutics Approval for Tyvaso DPI™ The US FDA approved United Therapeutics (UTHR) product Tyvaso DPI™ …

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

May 25, 2022 0

Alnylam Pharmaceuticals Alnylam Pharmaceuticals (ALNY) led the translation of RNA interference (RNAi) into a new class …

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

May 23, 2022 0

Regeneron Pharmaceuticals and Sanofi Announce FDA Approval of Dupixent® Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. …

Karyopharm Therapeutics: CHMP Recommended Approval of the Firm’s Product NEXPOVIO® for Multiple Melanoma in Europe.

May 20, 2022 0

Karyopharm Therapeutics Karyopharm Therapeutics (KPTI) and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, announced …

An Important Reminder from Vir Biotechnology

May 19, 2022 0

Vir Biotechnology Vir Biotechnology (VIR) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge …

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

May 19, 2022 0

Exelixis Press Release This press release covers a large part of Exelixis accomplishments, including important details …

Bear Market. Bad Market. Unpredictable Market.

May 17, 2022 0

Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from …

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s DIisease

May 10, 2022 0

Eisai and Biogen Inc: Lecanemab Eisai and Biogen Inc. (BIIB) announced that Eisai has completed the rolling …

Positive News for Two Undervalued Firms in the Prohost Portfolio

May 5, 2022 0

Exelixis CABOMETYX Approval Exelixis (EXEL) partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven Target Discovery Engine

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

Akero Therapeutics: Two Financing Transactions with Pfizer and Hercules Capital

Health Canada Approved Amylyx Pharmaceuticals’ Product ALBRIOZA for Amyotrophic Lateral Sclerosis

Inflation and the Stock Market. ASCO: Different Data’s Presentations Promising to Defeat Solid Tumors

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Vertex Pharmaceuticals and Type 1 Diabetes

Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News

The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Karyopharm Therapeutics: CHMP Recommended Approval of the Firm’s Product NEXPOVIO® for Multiple Melanoma in Europe.

An Important Reminder from Vir Biotechnology

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

Bear Market. Bad Market. Unpredictable Market.

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s DIisease

Positive News for Two Undervalued Firms in the Prohost Portfolio